Our Firm continues to hear from M2a Magnum hip recipients who have allegedly suffered serious complications, including metallosis, premature device failure, and the need for revision surgery.
New York, NY (PRWEB) June 18, 2013
Biomet hip lawsuit claims involving the M2a Magnum hip continue to move forward in a multidistrict litigation in U.S. District Court, Northern District of Indiana, Bernstein Liebhard LLP reports. According to court records, the litigation’s most recent status conference was held on June 17th, at which time the Court also convened a motions hearing and a tutorial on the scientific and technical issues pertinent to the Biomet hip replacement litigation. The proceeding’s next Status Conference has been scheduled for July 29, 2013. (In re: Biomet M2a Magnum Hip Implant Products Liability Litigation – MDL No. 2391)
“We are pleased to see that Biomet hip lawsuits are progressing. Our Firm continues to hear from M2a Magnum hip recipients who have allegedly suffered serious complications, including metallosis, premature device failure, and the need for revision surgery, due to this metal-on-metal hip implant,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is actively filing Biomet hip replacement lawsuits in the federal multidistrict litigation, and continues to offer free and confidential case evaluations to individuals who may have been injured by Biomet M2a Magnum implants.
Biomet Hip Lawsuits
Court records indicate that at least 308 Biomet hip lawsuits were pending in the federal litigation as of May 14, 2013. All of the lawsuits filed in the proceeding claim that the M 2a Magnum implant is prone to wear, and can generate high metal ion levels due to its metal-on-metal design. Biomet hip recipients have allegedly suffered metallosis and other adverse tissue reactions, premature device failure and additional complications that resulted in revision surgery to remove and replace the hip.
Metal-on-metal hip implants, like the Biomet M2a Magnum, are currently the subject of a U.S. Food & Drug Administration (FDA) safety review, which is being conducted amid a growing body of evidence that indicates the metal shed from such devices can cause premature failure of the hip, as well as numerous other complications. In January, the FDA advised that recipients of metal-on-metal hip implants undergo blood tests to determine their metal ion levels if they are suffering any symptoms that would indicate their hip could be failing. The FDA also proposed a new rule that would make all-metal hips ineligible for 510(k) approvals, a process which allowed metal-on-metal hips to come to market without first undergoing human clinical trials.*
Biomet hip replacement recipients who allegedly suffered injuries as a result of the M2a Magnum hip may be entitled to compensation for their medical expenses, lost wages and pain and suffering. To learn more about the litigation surrounding this and other metal-on-metal hip implants, please visit Bernstein Liebhard LLP’s website, or call one our attorneys today at 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP